Sign in

    Robert B. Ford

    Chairman of the Board and Chief Executive Officer at Abbott Laboratories
    Board
    Since 2021
    Age
    51 years
    Tenure
    Joined ABT as a corporate officer in 2008 and has held roles such as Executive Vice President of Medical Devices (2015 to 2018), President and Chief Operating Officer (2018 to 2020), President and CEO (2020 to 2021), and currently serves as Chairman of the Board and CEO since 2021.

    Also at Abbott Laboratories

    AW
    Andrea Wainer
    Executive Vice President, Rapid and Molecular Diagnostics
    DGS
    Daniel G. Salvadori
    Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products
    HLA
    Hubert L. Allen
    Executive Vice President, General Counsel, and Secretary

    About

    Robert B. Ford is the current Chairman of the Board and Chief Executive Officer at Abbott Laboratories, serving in this role since 2021. His leadership at the company is marked by a steady progression through increasingly responsible positions, showcasing his deep commitment to the growth and innovation at Abbott Laboratories.

    His professional journey began in 2008 when he was elected as a corporate officer. Over the years, he has held several key roles, progressing from Executive Vice President of Medical Devices between 2015 and 2018 to President and Chief Operating Officer from 2018 to 2020, and then transitioning to the combined role of President and CEO during 2020-2021.

    At 51 years old as of February 21, 2025 , his career reflects a blend of long-standing experience and dynamic leadership. While detailed personal background and education information are not provided, his professional tenure at Abbott Laboratories highlights a record of sustained development and strategic decision-making.

    This overview captures the essence of a leader who has not only advanced through multiple executive levels within the company but also played a key role during significant transitions in Abbott Laboratories’ recent history.

    $ABT Performance Under Robert B. Ford

    Past Roles

    OrganizationRoleDate RangeDetails
    Abbott LaboratoriesPresident and Chief Executive OfficerMarch 2020 - December 2021Held before becoming Chairman and CEO
    Abbott LaboratoriesPresident and Chief Operating Officer2018 - 2020Held prior to promotion
    Abbott LaboratoriesExecutive Vice President, Medical Devices2015 - 2018
    Abbott LaboratoriesSenior Vice President, Diabetes Care2014 - 2015
    Abbott LaboratoriesVarious leadership roles in Diagnostics, Nutrition, and Diabetes CareSince 1996Held roles across the U.S. and Latin America
    Abbott LaboratoriesElected Corporate OfficerSince 2008Became an elected officer

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Salary$1,500,000 Annual (2023)Fixed base salary
    Employer Contributions to Defined Contribution Plans$75,000 Annual (2023)Contributions to the defined contribution plans
    Earnings on Non-Qualified Defined Contribution Plans (net of reportable interest)$153,521 Annual (2023)Net earnings on non-qualified contributions
    Other Compensation (unspecified components)$208,392 Annual (2023)Represents remaining components of "All Other Compensation"

    Performance Compensation

    Data from  FY 2023

    Stock Awards for 2023

    DetailValueCitation
    Grant DateFebruary 17, 2023
    Grant Date Fair Value$7,436,600
    Number of Shares70,008 shares
    Vesting Schedule1/3 vesting per year over a 3-year term; 1/3 vested on February 29, 2024
    ConditionsVesting tied to a minimum return on equity target; full vest on death/disability

    Option Awards for 2023

    DetailValueCitation
    Grant DateFebruary 17, 2023
    Grant Date Fair Value$7,437,649
    Number of Options Granted276,082
    Exercise Price$106.24
    Closing Market Price on Grant Date$106.74
    Vesting Schedule1/3 after 1 year, 2/3 after 2 years, fully after 3 years
    ConditionsTime-based vesting; full vest on death/disability; subject to change in control provisions

    Non-Equity Incentive Plan Compensation for 2023

    Metric (Unit)WeightThresholdTargetMaximumActualScore (%)Citation
    Adjusted Sales (B USD)25%$40.00B$40.24B$40.50B$40.44B34.5%
    Adjusted Diluted EPS (USD)25%$4.30$4.40$4.50$4.4430.0%
    Adjusted ROA (%)10%13.3%13.5%13.9%13.7%12.5%
    Free Cash Flow (B USD)10%$4.8B$5.0B$5.2B$5.1B11.5%
    Diabetes Care Sales Growth (%)10%17.5%20.1%22.5%21.9%13.7%
    Key Cardiometabolic Product Sales Growth (%)10%80.4% of TargetTarget120.0% of TargetNot Achieved0%
    Human Capital Metrics10%Meet targetsAchievedAchievedAchieved10.0%
    • Total Goal Score: 112.20%
    • Bonus Payout Calculation: Base Salary $1,500,000 × Bonus Target of 175% × Total Goal Score 112.20% = $2,945,250
    • Evaluation Period: Performance assessed for 2023; payout processed in February 2024

    This comprehensive breakdown covers all performance-based elements for 2023 with precise metrics, targets, thresholds, vesting schedules, and payout details.